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Completely diverting portacaval shunt (Eck's 
fistula) in dogs causes hepatocyte atrophy, disruption 
of hepatocyte organelles, fatty infiltration and low-
grade hyperplasia. The effect of hepatic growth regu-
latory substances on these changes was assessed. by 
constantly infusing test substances for four postoper-
ative days after Eck's fistula into the detached left 
portal vein above the shunt. The directly infused left 
lobes were compared histopathologically with the 
untreated right lobes. In what has been called an 
hepatotrophic effect, stimulatory substances pre-
vented the atrophy and increased hepatocyte mitoses. 
Of the hormones tested, only insulin was strongly 
hepatotrophic; T 3 had a minor effect, and glucagon, 
prolactin, angiotensin n, vasopressin, norepinephrine 
and estradiol were inert. Insulin-like growth factor, 
hepatic stimulatory substance, transforming growth 
factor-a and hepatocyte growth factor (also known as 
hematopoietin A) were powerfully hepatotrophic, but 
epidermal growth factor had a barely discernible 
effect. Transforming growth facto~ was inhibitory, 
but tamomen, interleukin-1 and interleukin-2 had no 
effect. The hepatotrophic action of insulin was not 
altered when the insulin infusate was mixed with 
transforming growth factor-~ or tamomen. These 
experiments show the importance of in vivo in addition 
to in vitro testing of putative growth control factors. 
They illustrate how Eck's fistula model can be used to 
screen for such substances and possibly to help de-
lineate their mechanisms of action. (HEPATOLOGY 1991; 
14:665-670. ) 
Regulation of liver mass and the control of hepatic 
regeneration are poorly understood and presumably 
related processes. Hormones, soluble mediators and 
other substances that can influence hepatocyte size, 
proliferation or both have been identified with in vitro or 
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in vivo models of testing (1-10). Both test systems are 
important because no assurance exists that agents with 
in vitro activity are physiologically important. Moreover, 
substances with potent physiological activity in the 
intact animal may be inert when tested in vitro (11). 
An in vivo canine model of portacaval shunt (Eck's 
fistula) has been used previously to demonstrate striking 
hepatotrophic qualities of insulin (3, 4), crude (12) and 
partially purified (13) hepatic stimulatory substance 
(HSS) in the cytosol of regenerating livers and the 
immunosuppressive drugs cyclosporine (14) and FK 506 
(15). In this study, the same technique has been used to 
test most other growth factors that have been reported 
to influence hepatocyte proliferation. 
MATERIALS AND METHODS 
Experimental Model 
Conditioned female beagle dogs weighing 8.3 to 13 kg were 
anesthetized with intravenous sodium pentobarbital, 
halothane and nitrous oxide. The experimental model was as 
described previously (3, 4, 12, 14, 15). Side-to-side portacaval 
shunt was performed and converted to a functional end-to-side 
shunt by ligation of the portal vein above the anastomosis 
(Figure 1A). The main right and left portal veins were isolated, 
and the right vein was ligated. The left portal branch was 
cannulated with a 2.4 mm (internal diameter) cannula that 
was advanced for 1 em, secured and led through the abdominal 
wall to a calibrated and battery-driven constant infusion pump 
(Cormed II AIF, Cormed Inc., Murray Hill, NJ) that was 
incorporated into a nonrestricting light body cast. Test 
substances dissolved in saline modified by the addition of 
5 mmol/L ammonium acetate and 5 mg/L BSA (to avoid 
aggregation on the plastic tubing) were infused continuously at 
25 ml/day for 4 days beginning promptly after completion of 
the portacaval shunt. Previous experiments established that 
insulin and glucagon in the doses used, and both together, had 
no effect on blood sugar (4). In control experiments (data not 
shown) it was established that the vehicle is inert. The animals 
were given a sugar water diet ad libitum on the day of the 
operation and a regular diet thereafter. Before the animals 
were killed. hepatic and kidney function tests were obtained. 
Rises in serum creatinine or bilirubin or falls in serum albumin 
were not seen. Minor increases in AL T and alkaline phos-
phatase typical of Eck's fistula (16) were common. All dogs 
were active, ate normally and appeared clinically well. 
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A 
ECK Fistula Model for Post Operative Infusion 
into the Left Portal Vein (A) and into the Left 
and Right Portal Vein (B) 
Pump 
Pump 
'"" ~ 
Insulin ~ 
FIG. 1. Eck fistula model for postoperative infusion into the (A) left 
portal vein and into the (B) left and right portal vein. 
Pathological End Points 
Four days after portacaval shunt, 0.2 mCi/kg of intravenous 
eH) thymidine was given with a specific activity of 80 to 90 
Ci/mmol (Dupont New England Nuclear Research Products, 
Boston, MA). Two hours later, while the dogs were under 
sodium pentobarbital anesthesia, specimens were taken from 
left and right lobes of the liver and fixed in 10% normal 
buffered formalin. The dogs were killed with an intravenous 
bolus of potassium chloride. The patency of the anastomosis 
and the correct position of the catheter tip were confirmed. 
The liver tissue was processed and stained with hematoxylin 
and eosin. Autoradiography was carried out with Kodak NTB2 
liquid emulsion (Eastman Kodak, Rochester, NY) with an 
exposure time of at least 30 days. The number of replicating 
hepatocytes as an index of hepatocyte regeneration was 
determined by counting the number of (3H)thymidine-Iabeled 
nuclei per 1,000 hepatocytes. The size of individual hepato-
cytes (index of hypertrophy or atrophy) was determined by 
tracing out at least 500 midzonal liver cells prOjected on 
standard thickness paper, cutting out the individual silhou-
ettes and weighing each. This method has been shown to be 
accurate for determining hepatocyte cell size and has been 
validated by planimetry and studies of unicellular organisms, 
the size of which has been determined directly (2). 
In normal, unaltered dogs, 1.5 ± 0.5 (S.D.) labeled hepato-
cytes per 1,000 hepatocytes are present in the liver, with the 
size of midzonal hepatocytes being 0.16 ± 0.01 (S.D.) size 
units. Mter Eck's fistula, the replication rate is nearly tripled, 
and the hepatocyte size is almost halved within 4 days (4, 12, 
15), after which a stable state exists (17, 18). The exceptional 
reproducibility of these changes makes it easy to determine the 
effects of drugs on this transformation. Each experiment 
serves as its own control because the cell replication and size 
in the directly infused liver lobes can be compared with these 
measures in the contralateral uninfused lobes. 
Agents Tested 
The doses of insulin and glucagon were the same as those 
shown in earlier experiments not to cause changes in blood 
sugar (4). The amount of the other agents was guided by the 
previously determined effective dose by weight of HSS (13). 
Hormones (Table 1). Included in this group were: insulin 
(human regular semisynthetic, E.R. Squibb & Sons Inc., Prin-
ceton, NJ); glucagon, prolactin, vasopressin, norepinephrine 
estradiol and T 3' (Sigma Chemical Co., St. Louis, MO); and 
angiotensin II (Peninsula Laboratories, Belmont, CAl. 
Growth Factor Stimulator. (Table 2). These items included: 
HSS produced in our laboratory (11); insulin-like growth 
factor (lGF-II) (Collaborative Research, Inc., Bedford, MA); 
epidermal growth factor (EGF) (Collaborative Research, Inc.); 
transforming growth factor-a (TGF-a) (Peninsula Labora-
tories, Inc.); and hepatocyte growth factor (HGF, also called 
hepatopoietin A or HPTA), which was purified at Duke 
University, Durham, NC by George Michalopoulos (19). 
Growth Factor Inhibitors (Table 3). These inhibitors in-
cluded: tamoxifen (Sigma Chemical Co.); qdc-~I interleukin 
1 (IL-1) and interleukin 2 (IL-2) (Collaborative Research, 
Inc.). 
Stimulator-Inhibitor CombinatiollB (Table 4). In separate 
experiments, insulin, which was one of the most potent in vivo 
stimulators when used alone, was mixed with the qdc-~I 
which was the only unambiguously inhibitory substance that 
could be identified. The mixture was infused into the left portal 
branch at the same time that insulin alone was infused into the 
right portal branch (Figure 1B)' A similar experiment was 
performed with an insulin-tamoxifen mixture infused in one 
portal branch vs. insulin alone in the other. 
Statistical Analysis 
In each experimental group, the rate of cell renewal as 
quantitated by the number of labeled nuclei and the size units 
were compared between the left (infused) liver lobes vs. the 
right lobes that were not infused except in the bilateral 
infusion experiments (Figure 1B). Data were reported as 
mean ± S.D. The Student's one-tail t test was used to 
determine the significance of differences. A p value less than 
0.05 was considered significant. 
RESULTS 
Hormones 
Insulin was the only hormone that prevented the 
hepatocyte atrophy caused by portacaval shunt and 
provoked a major increase in hepatocyte proliferatlOn 
(Table 1). The hepatocytes on the insulin-protected side 
had intact organelles, less fat deposition and a higher 
concentration of glycogen. Glucagon had no effect. 
These results were the same as previously reported (3, 4, 
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TABLE 1. Hepatocyte size and autoradiographic labeling after continuous infusion of hormonea into the left portal vein 
branch of dogs with Eck's fistula 
No. of labeled hepatocytee per 1000 hepatocyte&" CeO size units" 
Group N Dolle qtday Left lobe Right lobe Left lobe Right lobe 
Prolactin 2 200 ng 3.95:t: 0.07 3.95:t: 0.06 0.100 :t: 0.01 0.097 :t 0.01 
Angiotensin II 2 100 ng 4.1 :t: 0.05 3.85:t: 0.06 0.101 :t: 0.01 0.098 :t 0.03 
Angiotensin II 1 200 ng 4.2 3.9 0.114 0.100 
Vasopressin 2 50 ng 3.95 :t 0.07 3.85:t 0.07 0.097 :t 0.01 0.093 :t: 0.01 
Norepinephrine 3 0.10 ng 3.73 :t 0.7 3.8 :t 0.7 0.104 :t: 0.02 0.104 :t 0.01 
Estradiol 3 700 ng 5.3:t 0.8 5.1 :t 0.4 0.099 :t: 0.01 0.099 :t: 0.01 
Ta 3 100 ng 7.02 :t O.g/' 4.1 :t 0.4 0.115 :t: 0.01 0.097 :t 0.01 
Insulin 5 0.43 units 13 :t 3.8e 4.6 :t 0.9 0.160 :t 0.02b 0.100 :t 0.02 
Glucagon 3 0.6mg 4.2 :t 1.5 4.3 :t 1.1 0.085 :t 0.01 0.082 :t 0.01 
aMean :t S.D. 
bp < 0.005. 
'p < 0.001. 
TABLE 2. Hepatocyte size and autoradiographic labeling after continuous infusion of growth stimulating factors into the 
left portal vein branch of dogs with Eck's fistula 
No. of labeled hepatocytes per 1000 hepatocyteS" Cell size unitS" 
Group N Dose ng!kg/day Left lobe Right lobe Left lobe Right lobe 
IGF-II 4 50 12.2 :t: O.lb 4.37 :t 0.51 0.147 :t O.Olb 0.094 :t 0.02 
IGF-II 1 100 12 4.2 0.152 0.093 
IGF-II 150 12.8 4 0.150 0.091 
EGF 4 50 4.8 :t 0.5' 3.92 :t 0.12 0.114 :t 0.005e 0.094 :t 0.01 
EGF 1 100 4.9 4.1 0.121 0.091 
EGF 1 150 5.2 4.0 0.119 0.100 
TGF-a 3 50 10.7 :t 0.4b 3.9 :t 0.4 0.136 :t 0.0012b 0.093 :t 0.009 
HSS 5 50 12.3 :t 0.03b 4.6 :t 0.008 0.148 :t 0.015b 0.08 :t 0.01 
HGF 2 50 12.0 :t O.lb 4.7 :t 0.12 0.146 :t 0.012 0.089 ± 0.02 
aMean :t S.D. 
bp < 0.001. 
c p < 0.05. 
TABLE 3. Hepatocyte size and autoradiographic labeling after continuous infusion of growth inhibiting factors into the left 
portal vein branch of dogs with Eck's fistula 
No. of labeled hepatocytes per 1000 hepatocyte&" Cell size unitS" 
Group N Dose ng!kg/day Left lobe 
Tamoxifen 3 1000 4.23 :t 0.45 
Tamoxifen 1 2000 4.2 
TGF-(3 3 5 2.4 :t 05b 
IL-l 2 5 4.4 :t 0.28 
IL-2 3 5 4.9 :t 1.3 
aMean :t S.D. 
bp < 0.05. 
14). At a dose of 100 ng/k~dayI T 3 caused proliferation 
to a much smaller degree, but it did not prevent atrophy. 
Prolactin. angiotensin II, vasopressin. norepinephrine 
and estradiol were inert at the doses used (Table 1). 
Growth Stimulation Factors 
The same dramatic effects caused by insulin were 
produced by 50 ng/k~day doses of IGF-II, TGF, HGF 
and HSS purified 381,000 times from the cytosol of 
regenerating rat hepatocytes. EGF had barely demon-
Right lobe 
4.03 :t 0.23 
3.9 
4.6 :t 0.8 
4.9 :t 1.3 
4.5 :t: 0.58 
Left lobe 
0.096 :t: 0.01 
0.103 
0.064 :t 0.02b 
0.119 ± 0.01 
0.112 :t: 0.01 
Right lobe 
0.093 :t: 0.01 
0.101 
0.103 :t: 0.01 
0.105 :t: 0.05 
0.109:t: 0.01 
strable activity (Table 2), which was not different within 
a dose range of 50 to 150 ng/k~dayK 
Growth Inhibitors 
At a dose of 5 ngikglday. TGF-!3 reduced by half 
the low-grade hyperplasia caused by portacaval shunt 
and caused further shrinkage of the already atrophic 
hepatocytes. At the same doses, activity of IL-1 and 
IL-2 could not be demonstrated. Tamoxifen was with-
out effect. 
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TABLE 4. Hepatocyte size and autoradiographic labeling after continuous infusion of insulin (0.42 IU/kg/day) into the right 
portal vein branch and insulin plus tamomen or TGF-Jl into the left portal branch 
No. of labeled hepatoeytes per 1000 hepatocyte. CeU size UDita 
Inhibitor Inhibitor dose Left lobe Right lobe Left 
sublltauce N nWkl/day (inhibitor side) 
Right (no inhibitor) lobe )obe 
Tamoxifen 1 2,000 9.8 
Tamoxifen 4,000 10.7 
qdc-~ 1 10 11.2 
qdc-~ 1 20 12.7 
Stimulator-Inhibitor Combinatio1l8 
In the double-infusion experiments shown in Figure 
IB, the hepatocyte proliferation and prevention of 
atrophy mediated by insulin were unaltered by the 
addition of tamoxifen or by the mixing of insulin with 
doses of TGF -~I which by themselves were inhibitory 
(Table 4). 
DISCUSSION 
An active test substance prevents the expected acute 
hepatocyte atrophy and organelle disruption in the 
in.fused liver lobes; in addition, the characteristically 
increased resting hepatocyte mitoses caused by Eck's 
fistula is doubled or tripled by the most potent additives. 
These so-called hepatotrophic responses have been 
described previously for insulin (3, 4), crude (12) or 
purified (13) cytosolic extract from regenerating livers 
and the immunosuppressive agents cyclosporine (14) 
and FK 506 (15). 
Only a limited number of agents possess these 
so-called hepatotrophic qualities. The observations 
herein reported have added IGF-II, TGF-a and HGF in 
nanogram quantities to the high potency substance list. 
Numerous others substances that have been reported to 
be strong stimulators in tissue culture or in some 
instances in intact animals (e.g., T 3) (1, 20) had little or 
no effect. T 3 (Table 1) caused low-grade hyperplasia, 
and EGF that stimulates hepatocytes in culture (21) 
had barely discernible activity in our model even when 
double and triple the planned 50 ng/day doses were given 
(Table 2). Although EGF resembles TGF-a structurally 
and functionally and has the same cell-surface receptor 
(22), its inactivity relative to TGF -a was not surprising. 
TGF-a is a stronger mitogen than EGF for hepatocytes 
in vitro (23), and in many other functions besides 
hepatocyte replication it is a stronger affector (24). 
Other putative stimulators that had little or no effect in 
Eck's fistula preparation included the hormones pro-
lactin (25), angiotensin II (26), vasopressin (7), norepi-
nephrine (6, 27), estradiol (28) and glucagon (29). 
In the "priming and progression" concept proposed by 
Fausto (30), the disparate results with in vitro and in 
vivo testing could reflect actions at different times in the 
cell cycle. In Fausto's nomenclature, initiators that 
activate the gO-gl transition within a few hours already 
may be in the liver or blood or else synthesized almost 
immediately after a regeneration stimulus (30). Ions, 
nutrients and growth regulators that tested negatively 
10.6 0.1511 0.1598 
11.1 0.1421 0.1387 
10.6 0.1593 0.1587 
11.2 0.1684 0.1696 
in our experiments could be in this category. Some of the 
progression phase factors in Fausto's scheme regulate 
not only gO-I but also the DNA synthesis and mitosis 
that follow in gl-S. Most of the powerful stimulators in 
our Eck's fistula model do not initiate replication in vitro 
but might best be termed" augmenters," acting solely or 
m.ainly at the gl-S interphase. 
An alternate classification scheme for liver mitogens is 
based on the actions of compounds on hepatocyte 
cultures. Complete mitogens in the alternative classifi-
cation of Michalopoulos (31) are stimulatory in chemi-
cally defined in vitro conditions, whereas his term 
"incomplete mitogen" (comitogen) is reserved for sub-
stances such as nonepinephrine, which are not directly 
mitogenic but enhance the effect of complete mitogens 
and/or counteract the effect of mitotic inhibitors (32). 
The comitogenic action of norepinephrine is strongly 
dependent on the presence of insulin (27), which 
possibly explains why a norepinephrine effect could not 
be seen in our Eck's fistula experiments. 
Depriving the liver of direct access to endogenous 
insulin is the single most important and most easily 
demonstrable cause for the changes that follow Eck's 
fistula (3,4, 12) or other more complex operations that 
put the liver in an insulinoprival state U6-18, 33·35). 
The crucial demonstration was that intraportally ad· 
ministered exogenous insulin by itself could prevent 
most of the changes of Eck's fistula (3, 4). However, in 
hepatocyte cultures, the principal and essential effect of 
insulin by itself is to maintain viable and healthy 
hepatocytes but with minimal or no mitogenicity 
(36-41). . 
IGF-II was of equal potency to insulin in the Eck's 
fistula model, although it also has little or no inherent 
mitogenicity in hepatocyte culture (42). IGF-II has been 
described in hepatomas in the woodchuck hepatitis 
model (43), and its role in modulating normal and 
neoplastic hepatocytes bears investigation. Additionally, 
strong evidence exists that IGF -I and IGF -II can act not 
only through their own receptors but also through the 
insulin receptor in many in vivo and in vitro systems 
(44). Thus the strong effects of IGF·II in Eck's fistula 
system herein reported may reflect the well-known 
insulin mimetic role of this substance. Even the smallest 
dose used had a full hepatatrophic effect. 
The critical value of such in vivo testing is evident 
from the results herein reported. Of the seven most 
potent hepatotrophic substances identified so far with 
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Eck's fistula model, only TGF-a (45) and HGF (19) also 
have had strong mitogenic properties in tissue culture. 
The demonstration that HGF also had a strong effect in 
Eck's fistula model is the first evidence of its in vivo 
potency. HGF is produced in multiple sites, including 
the exocrine portion of the pancreas (46), and its 
physiological role remains to be determined. However, 
using in vitro testing for growth effects, researchers 
might pass over as unexciting not only insulin and 
IGF-II but also cyclosporine (47), FK 506 (47) and HSS. 
However, all five are in the first rank of Michalopoulos 
comitogens. 
Aside from the fact that HSS is not stimulatory in 
hepatocyte culture (10), a comitogenic role ofHSS (using 
the Michalopoulos definition) has been suspected on 
other grounds. In the experiments herein reported, HSS 
was purified from the cytosol of regenerating rat livers 
and found to be potent in dogs, showing that it is not 
species specific. In dogs, the crude cytosol from the re-
sidual liver fragment does not possess stimulatory ac-
tivity until 48 hr, reaching maximum potency after 72 hr 
as determined in the canine Eck's fistula model (12) or 
by the augmentation of hepatic regeneration in a second 
dog after subtotal hepatectomy (48). The time when he-
patic regeneration in dogs reaches its peak is 3 days (49). 
The list of other potential comitogens that could be 
studied with Eck's fistula model is long and includes 
hundreds of xenobiotics such as phenobarbital and 
peroxisome proliferators (50). Although these agents are 
not mitogenic in vitro, they stimulate DNA synthesis in 
the liver in vivo and function as powerful hepatic tumor 
promoters. 
In addition to screening for stimulatory compounds, 
Eck's fistula model should be valuable for the in vivo 
screening and study of substances that are inhibitory. 
Against the background of heightened cell renewal, 
qdc-~I a powerful inhibitor of hepatocyte proliferation 
in vitro (51, 52), was shown in our current experiments 
to inhibit ongoing proliferation in addition to reducing 
further the size of the already atrophic hepatocytes. The 
other test substances that were without activity in our 
Eck's fistula experiments but which have been reported 
to be inhibitory in tissue culture systems were tamoxifen 
(28), IL-l and IL-2 (53). 
Finally, the feasibility of using this model to study the 
interrelation of stimulators and inhibitors was demon-
strated. In our experiments the reduction of hepatocyte 
replication and size by qdc-~ was overridden by insulin 
when the two agents were given together. It will be 
important to see the extent to which these interactions 
are dose related and time related and to test the 
interactions of growth inhibitors with other stimulatory 
substances. 
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